Cardiff Oncology Inc (NASDAQ:CRDF) saw an upside of 0.62% to close Tuesday at $1.62 after adding $0.01 on the day. The 5-day average trading volume is 831,540 shares of the company’s common stock. It has gained $1.6670 in the past week and touched a new high 2 times within the past 5 days. An average of 337,650 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 770,236.
CRDF’s 1-month performance is -11.96% or -$0.2200 on its low of $1.5500 reached on 09/26/23. The company’s shares have touched a 52-week low of $1.20 and high of $2.79, with the stock’s rally to the 52-week high happening on 08/08/23. YTD, CRDF has achieved 15.71% or $0.2200 and has reached a new high 9 times. However, the current price is down -41.94% from the 52-week high price.
Valuation Metrics
CRDF stock has a beta of 1.71. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 176.54 while the price-to-book (PB) in the most recent quarter is 0.84.
Cardiff Oncology Inc’s quick ratio for the period ended June 29 was 10.16, with the current ratio over the same period at 10.16. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.02, while the total debt to equity was 0.03.. In terms of profitability, the gross margin trailing 12 months is 22.57%. The trailing 12-month EBITDA margin is -10285.49% while for the period ending June 29, Cardiff Oncology Inc’s operating margin was -10350.73%. The firm’s gross profit as reported stood at $0.39 million against revenue of $0.39 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 6.36% to -$11.16 million, while revenue of -$11.23 million was -0.63% off the previous quarter. Analysts expected CRDF to announce -$0.26 per share in earnings in its latest quarter, but it posted -$0.25, representing a 3.80% surprise. EBITDA for the quarter stood at more than -$12.35 million. CRDF stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 10.88 million, with total debt at $2.44 million. Shareholders hold equity totaling $44.68 million.
Let’s look briefly at Cardiff Oncology Inc (CRDF) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 38.06% to suggest the stock is trending Neutral, with historical volatility in this time period at 47.98%.
The stock’s 5-day moving average is $1.6220, reflecting a -0.61% or -$0.0100 change from its current price. CRDF is currently trading -10.00% above its 20-day SMA, -12.90% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +13.29% and SMA200 by+14.08%.
Stochastic %K and %D was 9.40% and 7.53% and the average true range (ATR) pointed at 0.1114. The RSI (14) points at 42.17%, while the 14-day stochastic is at 14.92% with the period’s ATR at 0.1220. The stock’s 9-day MACD Oscillator is pointing at -0.0528 and -0.1070 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Cardiff Oncology Inc (NASDAQ: CRDF), William Blair launched coverage with an Outperform rating. Analysts offering their rating for CRDF stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CRDF as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 4 have offered a “buy” rating.
What is CRDF’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $12.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for Cardiff Oncology Inc (CRDF) stock is $7.33.
